Hepatic Encephalopathy
Hepatic Encephalopathy Market

Hepatic Encephalopathy is a brain disorder that develops in some individuals with liver disease.

When the liver doesn't work properly, toxins build up in the blood. These toxins can travel to the brain and affect brain function. People with Hepatic Encephalopathy may seem confused.


Hepatic Encephalopathy Epidemiological Segmentation

 

The Epidemiological Segmentation of Hepatic Encephalopathy in 7MM from 2018 to 2030 is segmented as:-


  • Total Number of Hepatic Encephalopathy Cases 
  • Gender-specific Cases of Hepatic Encephalopathy
  • Age-Specific Cases of Hepatic Encephalopathy
  • Type-Specific Cases of Hepatic Encephalopathy


Hepatic Encephalopathy Epidemiological Insights Observed in 2018

 

  • The total diagnosed prevalent cases of Cirrhosis in 7MM were observed to be 850,135.
  • The total number of Hepatic Encephalopathy cases in the United States was 201,830.
  • The total number of Hepatic Encephalopathy cases in the United Kingdom was estimated to be 27,313.
  • The total number of Hepatic Encephalopathy cases in France was 22,143.
  • In Germany, the total number of Hepatic Encephalopathy cases was found to be 26,407.
  • The total number of Hepatic Encephalopathy cases in Japan was 29,454.
  • The total number of Hepatic Encephalopathy cases in Spain was observed to be 9,698.
  • In the United States, the Gender-specific cases of Hepatic Encephalopathy in males were observed to be 146,730 cases, and in females, it was observed to be 55,100 cases.
  • In the United States, the Age-Specific cases of Hepatic Encephalopathy in people aging between 45–54 years were found to be 83,558 cases, whereas in people with age less than 25 years were observed to be 6,055 cases.

 

Hepatic Encephalopathy Market

 

The market size of Hepatic Encephalopathy in the 7MM was found to be USD 1,261 million in 2018.

 

Hepatic Encephalopathy Market Drivers


  • Increasing diagnosed prevalence
  • Emergence in the novel treatment target
  • Less competition among therapies 

 

Hepatic Encephalopathy Market Barriers


  • Adverse events associated with the current therapies
  • Pipeline not very robust
  • Disease burden
  • Challenges in diagnosis 


Hepatic Encephalopathy Emerging Drugs

 

The emerging drugs of the Hepatic Encephalopathy market are:


  • AXA1665
  • GR3027 (Golexanolone)
  • MNK-6105/MNK-6106 (OCR-002)
  • VE303, and others


Hepatic Encephalopathy Key Players

 

The key players working in the Hepatic Encephalopathy market are:


  • Axcella Health
  • Umecrine Cognition
  • Mallinckrodt Therapeutics
  • Vedanta Biosciences
  • Patricia Bloom, and others